Advertisement

International Ophthalmology

, Volume 38, Issue 6, pp 2553–2562 | Cite as

Comparison of the neuroprotective effects of brimonidine tartrate and melatonin on retinal ganglion cells

  • Deniz Marangoz
  • Elif Guzel
  • Signem Eyuboglu
  • Asli Gumusel
  • Ismail Seckin
  • Ferda Ciftci
  • Bayram Yilmaz
  • Ilgaz Yalvac
Original Paper
  • 204 Downloads

Abstract

Purpose

We aimed to compare the neuroprotective effects of brimonidine tartrate (BRT) and melatonin (MEL) on retinal ganglion cells (RGCs) in a rat glaucoma model.

Methods

Thirty-six adult Wistar albino rats were allocated into six groups: control (C), glaucoma (G), BRT, MEL, G + BRT and G + MEL. After establishing the glaucoma model, intraocular pressure (IOP) of all animals measured at day 4 and day 30 was compared statistically with day 0 and day 4, respectively. Prior to sacrification at day 30 for histological evaluation and TUNEL analysis, retrograde labeling of non-apoptotic RGCs with 3% Fluorogold was performed and RGCs were evaluated under fluorescein microscope.

Results

IOP measurements at day 4 were significantly higher than basal measurements in all glaucoma groups. BRT alone induced a time-dependent decrease in IOP (p < 0.05), while MEL alone failed to reduce IOP. However, both BRT and MEL reduced IOP in the presence of glaucoma at day 30 (p < 0.05). BRT treatment significantly reversed the reduced non-apoptotic RGC counts (p < 0.01) and increased TUNEL-positive RGCs (p < 0.001) to control group levels in the presence of glaucoma. However, no statistical significance was found between groups G and G + MEL considering 3% Fluorogold-labeled cell counts and apoptotic index values.

Conclusion

Our study revealed that systemic administration of BRT also has an IOP reducing effect. MEL has no neuroprotective effect on RGCs; on the other hand, BRT acts as a neuroprotective agent against glaucomatous injury, when applied systemically.

Keywords

Glaucoma Neuroprotection Retinal ganglion cell Melatonin Brimonidine tartrate 

Notes

Acknowledgements

We would like to express our sincere thanks toward Elif Cigdem Kaspar who devoted her time and knowledge in statistical analysis of the project.

Funding

Council of Science and Research, Yeditepe University Faculty of Medicine funded this study. (Grant number: 68774383-001/1076).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

Study protocol was approved by Yeditepe University Ethics Committee for Animal Studies and Research. All procedures performed in studies involving animals were in accordance with the ethical standards of Animal Studies Research Laboratory, Yeditepe University, at which the studies were conducted.

References

  1. 1.
    Quigley HA, Broman AT (2006) The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 90:262–267CrossRefGoogle Scholar
  2. 2.
    Ramulu PY, Corcoran KJ, Corcoran SL, Robin AL (2007) Utilization of various glaucoma surgeries and procedures in Medicare beneficiaries from 1995 to 2004. Ophthalmology 114:2265–2270CrossRefGoogle Scholar
  3. 3.
    WoldeMussie E, Ruiz G, Wijono M, Wheeler LA (2001) Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci 42:2849–2855PubMedGoogle Scholar
  4. 4.
    Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E (2003) Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 121:48–56CrossRefGoogle Scholar
  5. 5.
    Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M (2002) Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 120:1268–1279CrossRefGoogle Scholar
  6. 6.
    Yoles E, Wheeler LA, Schwartz M (1999) Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci 40:65–73PubMedGoogle Scholar
  7. 7.
    Wheeler L, WoldeMussie E, Lai R (2003) Role of alpha-2 agonists in neuroprotection. Surv Ophthalmol 48(Suppl 1):S47–S51CrossRefGoogle Scholar
  8. 8.
    Donello JE, Padillo EU, Webster ML, Wheeler LA, Gil DW (2001) α(2)-Adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J Pharmacol Exp Ther 296:216–223PubMedGoogle Scholar
  9. 9.
    Lafuente MP, Villegas-Perez MP, Sobrado-Calvo P, Garcia-Aviles A, Miralles de Imperial J, Vidal-Sanz M (2001) Neuroprotective effects of α(2)-selective adrenergic agonists against ischemia-induced retinal ganglion cell death. Invest Ophthalmol Vis Sci 42:2074–2084PubMedGoogle Scholar
  10. 10.
    Chiquet C, Claustrat B, Thuret G, Brun J, Cooper HM, Denis P (2006) Melatonin concentrations in aqueous humor of glaucoma patients. Am J Ophthalmol 142(325–327):e1Google Scholar
  11. 11.
    Tosini G, Pozdeyev N, Sakamoto K, Iuvone PM (2008) The circadian clock system in the mammalian retina. BioEssays 30:624–633CrossRefGoogle Scholar
  12. 12.
    Arendt J, Skene DJ (2005) Melatonin as a chronobiotic. Sleep Med Rev 9:25–39CrossRefGoogle Scholar
  13. 13.
    Hardeland R, Cardinali DP, Srinivasan V, Spence DW, Brown GM, Pandi-Perumal SR (2011) Melatonin—a pleiotropic, orchestrating regulator molecule. Prog Neurobiol 93:350–384CrossRefGoogle Scholar
  14. 14.
    Castrillon PO, Cardinali DP, Pazo D, Cutrera RA, Esquifino AI (2001) Effect of superior cervical ganglionectomy on 24-h variations in hormone secretion from the anterior hypophysis and in hypothalamic monoamine turnover during the preclinical phase of Freund’s adjuvant arthritis in rats. J Neuroendocrinol 13:288–295CrossRefGoogle Scholar
  15. 15.
    Park SW, Lee HS, Sung MS, Kim SJ (2012) The effect of melatonin on retinal ganglion cell survival in ischemic retina. Chonnam Med J 48:116–122CrossRefGoogle Scholar
  16. 16.
    Crooke A, Huete-Toral F, Martinez-Aguila A, Martin-Gil A, Pintor J (2013) Melatonin and its analog 5-methoxycarbonylamino-N-acetyltryptamine potentiate adrenergic receptor-mediated ocular hypotensive effects in rabbits: significance for combination therapy in glaucoma. J Pharmacol Exp Ther 346:138–145CrossRefGoogle Scholar
  17. 17.
    Martinez-Aguila A, Fonseca B, Perez de Lara MJ, Pintor J (2016) Effect of melatonin and 5-Methoxycarbonylamino-N-Acetyltryptamine on the intraocular pressure of normal and glaucomatous mice. J Pharmacol Exp Ther 357:293–299CrossRefGoogle Scholar
  18. 18.
    Chesnokova NB, Beznos OV, Lozinskaya NA et al (2017) Novel agonists of melatonin receptors as promising hypotensive and neuroprotective agents for therapy of glaucoma. Biomed Khim 63:75–80CrossRefGoogle Scholar
  19. 19.
    Ramirez-Rodriguez G, Klempin F, Babu H, Benitez-King G, Kempermann G (2009) Melatonin modulates cell survival of new neurons in the hippocampus of adult mice. Neuropsychopharmacology 34:2180–2191CrossRefGoogle Scholar
  20. 20.
    Koc S, Cayli S, Aksakal C et al (2016) Protective effects of melatonin and selenium against apoptosis of olfactory sensory neurons: a rat model study. Am J Rhinol Allergy 30:62–66CrossRefGoogle Scholar
  21. 21.
    Buendia I, Gomez-Rangel V, Gonzalez-Lafuente L et al (2015) Neuroprotective mechanism of the novel melatonin derivative Neu-P11 in brain ischemia related models. Neuropharmacology 99:187–195CrossRefGoogle Scholar
  22. 22.
    Koh PO (2008) Melatonin prevents ischemic brain injury through activation of the mTOR/p70S6 kinase signaling pathway. Neurosci Lett 444:74–78CrossRefGoogle Scholar
  23. 23.
    Borlongan CV, Yamamoto M, Takei N et al (2000) Glial cell survival is enhanced during melatonin-induced neuroprotection against cerebral ischemia. Faseb J 14:1307–1317CrossRefGoogle Scholar
  24. 24.
    Chetsawang B, Govitrapong P, Ebadi M (2004) The neuroprotective effect of melatonin against the induction of c-Jun phosphorylation by 6-hydroxydopamine on SK-N-SH cells. Neurosci Lett 371:205–208CrossRefGoogle Scholar
  25. 25.
    Mayo JC, Sainz RM, Uria H, Antolin I, Esteban MM, Rodriguez C (1998) Inhibition of cell proliferation: a mechanism likely to mediate the prevention of neuronal cell death by melatonin. J Pineal Res 25:12–18CrossRefGoogle Scholar
  26. 26.
    Shukla M, Boontem P, Reiter RJ, Satayavivad J, Govitrapong P (2017) Mechanisms of melatonin in alleviating alzheimer’s disease. Curr Neuropharmacol 15(7):1010–1031CrossRefGoogle Scholar
  27. 27.
    Weishaupt JH, Bartels C, Polking E et al (2006) Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res 41:313–323CrossRefGoogle Scholar
  28. 28.
    Ozdemir D, Tugyan K, Uysal N et al (2005) Protective effect of melatonin against head trauma-induced hippocampal damage and spatial memory deficits in immature rats. Neurosci Lett 385:234–239CrossRefGoogle Scholar
  29. 29.
    Erten SF, Kocak A, Ozdemir I, Aydemir S, Colak A, Reeder BS (2003) Protective effect of melatonin on experimental spinal cord ischemia. Spinal Cord 41:533–538CrossRefGoogle Scholar
  30. 30.
    Lee MC, Chung YT, Lee JH, Jung JJ, Kim HS, Kim SU (2001) Antioxidant effect of melatonin in human retinal neuron cultures. Exp Neurol 172:407–415CrossRefGoogle Scholar
  31. 31.
    Siu AW, Ortiz GG, Benitez-King G, To CH, Reiter RJ (2004) Effects of melatonin on the nitric oxide treated retina. Br J Ophthalmol 88:1078–1081CrossRefGoogle Scholar
  32. 32.
    Dardiotis E, Panayiotou E, Feldman ML et al (2013) Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration. Neurosci Lett 548:170–175CrossRefGoogle Scholar
  33. 33.
    Hernandez M, Urcola JH, Vecino E (2008) Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments. Exp Eye Res 86:798–806CrossRefGoogle Scholar
  34. 34.
    Pinar-Sueiro S, Urcola H, Rivas MA, Vecino E (2011) Prevention of retinal ganglion cell swelling by systemic brimonidine in a rat experimental glaucoma model. Clin Exp Ophthalmol 39(8):799–807CrossRefGoogle Scholar
  35. 35.
    Unlu M, Aktas Z, Gocun PU, Ilhan SO, Hasanreisoglu M, Hasanreisoglu B (2016) Neuroprotective effect of systemic and/or intravitreal rosuvastatin administration in rat glaucoma model. Int J Ophthalmol 9(3):340–347PubMedPubMedCentralGoogle Scholar
  36. 36.
    Mittag TW, Danias J, Pohorenec G et al (2000) Retinal damage after 3 to 4 months of elevated intraocular pressure in a rat glaucoma model. Invest Ophthalmol Vis Sci 41:3451–3459PubMedGoogle Scholar
  37. 37.
    Lambert WS, Ruiz L, Crish SD, Wheeler LA, Calkins DJ (2011) Brimonidine prevents axonal and somatic degeneration of retinal ganglion cell neurons. Mol Neurodegener 6:4CrossRefGoogle Scholar
  38. 38.
    Danesh-Meyer HV (2011) Neuroprotection in glaucoma: recent and future directions. Curr Opin Ophthalmol 22:78–86CrossRefGoogle Scholar
  39. 39.
    Gao H, Qiao X, Cantor LB, WuDunn D (2002) Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch Ophthalmol 120:797–803CrossRefGoogle Scholar
  40. 40.
    Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA (2008) α2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest Ophthalmol Vis Sci 49:4515–4522CrossRefGoogle Scholar
  41. 41.
    Lee KY, Nakayama M, Aihara M, Chen YN, Araie M (2010) Brimonidine is neuroprotective against glutamate-induced neurotoxicity, oxidative stress, and hypoxia in purified rat retinal ganglion cells. Mol Vis 16:246–251PubMedPubMedCentralGoogle Scholar
  42. 42.
    Baba K, Pozdeyev N, Mazzoni F et al (2009) Melatonin modulates visual function and cell viability in the mouse retina via the MT1 melatonin receptor. Proc Natl Acad Sci USA 106:15043–15048CrossRefGoogle Scholar
  43. 43.
    Alcantara-Contreras S, Baba K, Tosini G (2011) Removal of melatonin receptor type 1 increases intraocular pressure and retinal ganglion cells death in the mouse. Neurosci Lett 494:61–64CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V., part of Springer Nature 2017

Authors and Affiliations

  1. 1.Department of Ophthalmology, Faculty of MedicineYeditepe UniversityBeşiktaş-IstanbulTurkey
  2. 2.Department of Histology and EmbryologyCerrahpasa Faculty of Medicine, Istanbul UniversityFatih-IstanbulTurkey
  3. 3.Department of Physiology, Faculty of MedicineYeditepe UniversityIstanbulTurkey

Personalised recommendations